1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
Real-time Estimate Cboe BZX  -  05/19 10:32:28 am EDT
242.29 USD   -0.69%
05/18AMGEN INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/16AMGEN INC. : Ex-dividend day for
FA
05/13Avantor Names Jonathan Peacock Chairman
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen Inc.'s LUMAKRAS Receives Approval in Japan for Patients with KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

01/20/2022 | 04:30am EDT

Amgen Inc. announced that LUMAKRAS® (sotorasib) has been approved in Japan for the treatment of KRAS G12C-mutated positive, unresectable, advanced and/or recurrent non-small cell lung cancer (NSCLC) that has progressed after systemic anticancer therapy. The approval by the Japan Ministry of Health, Labour and Welfare (MHLW) is based on positive results from the Phase 2 CodeBreaK 100 clinical trial in NSCLC, the trial conducted to date for patients with the KRAS G12C mutation. Based on the approved label in Japan, LUMAKRAS 960 mg, orally administered once-daily, demonstrated an objective response rate (ORR) of 37% (95% CI: 28.8-46.6) in 123 evaluable patients (including 10 Japanese patients with a data cutoff date: Sept. 1, 2020). Adverse reactions were observed in 128 (67%) of 190 patients† (including 13 Japanese patients). The most common adverse reactions (incidence = 5%) were diarrhea (28%), nausea, increased alanine aminotransferase (ALT) and increased aspartate aminotransferase (AST) (16% each), fatigue (11%), increased blood alkaline phosphatase (8%), vomiting (7%) and abdominal pain (5%).


© S&P Capital IQ 2022
All news about AMGEN INC.
05/18AMGEN INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/16AMGEN INC. : Ex-dividend day for
FA
05/13Avantor Names Jonathan Peacock Chairman
MT
05/12Amgen and lance bass partner to encourage people to do a 'double take' to recognize the..
PR
05/12BridgeBio Inks BBP-398 License With Bristol Myers
DJ
05/11TRANSCRIPT : Amgen Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-202..
CI
05/11INSIDER SELL : Amgen
MT
05/10Pfizer to pay $11.6 bln for Biohaven to tap migraine market
RE
05/10Mizuho Securities Lifts Amgen's Price Target to $208 From $202, Citing Repatha Peak Rev..
MT
05/09Amgen announces webcast of 2022 bank of america healthcare conference
AQ
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2022 26 205 M - -
Net income 2022 6 905 M - -
Net Debt 2022 26 803 M - -
P/E ratio 2022 19,2x
Yield 2022 3,11%
Capitalization 130 B 130 B -
EV / Sales 2022 6,00x
EV / Sales 2023 5,67x
Nbr of Employees 24 200
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Last Close Price 243,96 $
Average target price 246,55 $
Spread / Average Target 1,06%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Senior VP-Translational Sciences & Oncology
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.8.44%130 323
JOHNSON & JOHNSON2.59%461 811
PFIZER, INC.-14.65%282 789
ABBVIE INC.12.58%269 361
ELI LILLY AND COMPANY6.87%265 718
ROCHE HOLDING AG-15.26%264 329